Scaffdex Oy and Conmed Linvatec Biomaterials Sign a Licensing Agreement of Commercialization and Clinical Data of Joint Prosthesis Innovation
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Scaffdex Oy and Conmed Linvatec Biomaterials have signed a licensing agreement of commercialization and clinical data of joint prosthesis innovation. Target of Scaffdex Oy is CE marking and launch of this product by end of 2010.
Joint prosthesis replaces small joints in hand and foot and it has been tested clinically for example in rheumatoid arthritis patients. Tampere University Hospital, Hospital of Foundation of Rheumatoid Arthritis in Heinola and clinics in Germany and Italy participated these international clinical trials.
Joint prosthesis replaces small joints in hand and foot and it has been tested clinically for example in rheumatoid arthritis patients. Tampere University Hospital, Hospital of Foundation of Rheumatoid Arthritis in Heinola and clinics in Germany and Italy participated these international clinical trials.
